TP53 and neoplasm: In addition, mutations in classical oncogenes such as MYC, TP53, and KRAS cause tumor cells to evade cell cycle regulation and apoptotic signaling, which in turn affects the progression of programmed cell death in tumor cells, resulting in continued disease progression [71–73].